Effect of different doses of gadolinium contrast agent on clinical outcomes in MS.
Nathalie Chantal AckermansCarolyn TaylorRoger TamRobert CarruthersShannon KolindHeejun KangMark S FreedmanDavid Kb LiAnthony L TraboulseePublished in: Multiple sclerosis journal - experimental, translational and clinical (2019)
There were no differences in the disability progression measures between the two cohorts, indicating that gadolinium does not result in greater clinical worsening in SPMS after a two-year period.